



# Advancing Responsible Self-Care

Annual Report

2023-2024



# CHP Australia Purpose & Mission

Consumer Healthcare Products Australia (CHP Australia) is the peak body and lead industry voice representing manufacturers and distributors of nonprescription and over-the-counter medicines and the consumer healthcare products sector. We champion the availability of safe, reliable, and evidence-based self-care products to empower Australians in managing their health and wellbeing proactively.

CHP Australia advocates for self-care as a core principle of national health policy, recognising that 90% of Australians rely on over 14,000 nonprescription products available in pharmacies, supermarkets, and convenience stores.

Through education, advocacy, research, and partnerships, we support Australia's healthcare system with robust policies, evidence-based solutions, and strong consumer health literacy.

## Purpose

Safe and accessible self-care options for all Australians



## Mission

To advance the health and wellbeing of Australians by ensuring access to safe, reliable and evidence-based products and solutions



# CHP Australia Strategic Goals 2024–2026

Improve the Health of Australians by  
Advancing Consumer Self-Care

**1** Actively Shape the Regulatory  
Environment to Advance Self-Care

**2** Actively Shape Government  
Policy to Advance Self-Care

**3** Innovate Service Delivery to  
Strengthen Membership Base

Chair and CEO's Message

AdCheck Service - Launch of TVC classification

**VOICE OF INDUSTRY**

Setting the Industry Agenda

Leading on Issues Management

**REGULATORY ENVIRONMENT**

Driving Regulatory Reform

**SUSTAINABILITY**

**PARTNERSHIPS**

**CHP AUSTRALIA**

Board

Subcommittees and Working Groups

Your Support Team

Events

Contact Details

## Chair and CEO's Message

As we reflect on the past year it is clear that it has been a period of key milestones and achievements for Consumer Healthcare Products Australia.

We have much to celebrate. We have expanded our reach, broadening our impact and delivering value for our members. None of these accomplishments would have been possible without the support of our members and the dedication of our talented team whose tireless efforts have driven our success. Together we have navigated challenges, embraced new opportunities and influenced the industry environment for the better.

### New strategic plan

The Board conducted a major strategic review at the end of 2023 to set the goals and direction for the next 3 years. The primary objective of the 2024-2026 plan is to improve the health of Australians by advancing responsible self-care. This is to be achieved by focusing on the drivers behind self-care – empowerment through improving health and medicines literacy.

The three main pillars of the strategic plan are:

- Actively shape the therapeutic goods regulatory environment to advance self-care. The focus of this pillar is the consumer healthcare products regulatory framework – OTCs, complementary medicines, and devices - and the aim is to ensure best-practice regulation with appropriate emphasis on both benefit and risk.
- Actively shape government policy to advance self-care and the key focus areas are the recognition of self-care in national health policy, environmental sustainability and manufacturing and export policy.
- The main thrust of the third pillar is the sustainability of CHP Australia – to innovate service delivery to members, to enhance the value proposition and to secure the long-term viability of the organisation.

### Sounding our voice in Canberra

Our Self-Care Networking Breakfast in Parliament House was well-attended by parliamentarians, their staff, and industry partners. The event provided an opportunity to showcase our joint partnerships with consumers and pharmacy to advance self-care.

Prof Tony Lawler, Deputy Secretary of the Health Products Regulation Group (which includes the TGA) was the guest of honour at our members-only Roundtable Luncheon in May. This was the launch event for our 50th anniversary celebrations. Members were able to directly raise industry issues and concerns with Prof Lawler. The event was another demonstration of industry's long-standing collaborative relationship with the TGA.

### Driving regulatory reform

We continued to influence regulatory outcomes at a time of unprecedented reform. Our work with members, the TGA and other stakeholders drives outcomes that are practical, proportionate,

effective and implemented within realistic timeframes. In the 12 months since July 2023, we had over 200 meetings with external stakeholders, including over 50 meetings with the TGA. In the same period, we considered 61 regulatory consultations and made submissions in relation to 39.

Advertising continues to be a major concern for members. Throughout the year, our advocacy has involved participation in the TGA consultations, advice to members, member workshops, meetings with the TGA and meetings with other stakeholders. In particular, our membership of the Therapeutic Goods Advertising Consultative Committee (TGACC) has allowed us to influence discussions and to obtain valuable insights for our members. Throughout the year we continued to assist members and collaborate with stakeholders to facilitate successful switch applications.

### Sustainability

Sustainability and the impact of our industry on the environment remains a key priority for CHP Australia. We are supporting members' sustainability objectives in relation to plastics and packaging in response to calls from state governments for greater circularity in the management of products and packaging. We are collaborating with our other industry partners to ensure alignment in pursuing sensible regulatory interventions.

### Advancing self-care – working at the policy as well as grassroots level

Self-care embedded in national health policy remains a key strategic priority. We are pursuing policy reforms primarily through the Australian Self-Care Alliance of which we are a founding member and represented on the board. The Alliance firmly established its credentials as an important voice in the self-care policy debate and is steadily increasing its membership to ensure the broadest stakeholder representation in the healthcare environment.

The Alliance is pursuing the development and implementation of the nine policy focus areas identified in the National Self-Care Policy Blueprint.

Two of the areas have already gained government attention. The development of a National Health Literacy Strategy commenced under the previous government and has progressed under the current government. The Government also launched public consultation in relation to the development of a consumer engagement strategy.

At grassroots consumer level we entered into the next major phase of our longstanding collaboration with Life Education. We supported the development and rollout of a first of its kind anti-vaping education program, Take A Breath. The roll-out commenced in January 2024 across Australia and aims to reach 20,000 year 5 and 6 students in the first year.

Our much-valued partnership with Sydney North Primary Health Network is continuing through the GPs in High Schools program to raise medicines literacy amongst year 11 students.

### Research

Our Strategic Self-Care Research Program continued to be rolled out with the commencement of a 2-year project to develop a model to enhance consumer self-care behaviour in the community pharmacy setting using digital technology, including AI. This project is conducted in partnership with Sydney North Primary Health Network, community pharmacy and consumers.

### Acknowledgements

We would like to thank our members for their support over the past year. We are fully aware of the significant investment, financial as well as personal engagement in committee activities, which are crucial in ensuring effective representation of individual members and the industry more broadly.

We also thank the CHP Australia board for its guidance and support for the secretariat team. And finally, a word of sincere thanks to the secretariat team for their dedication and commitment.

As we look forward, we remain focused on our mission and energised by the potential for even greater achievements in the future.



**Phil Lynch**  
Chair



**Deon Schoombie**  
Chief Executive Officer

## AdCheck Service- Launch of TVC classification

The last 4 years since AdCheck's launch has seen the service go from strength to strength. Feedback from users has been overwhelmingly positive.

Several clients have embraced the TVC classification service, appreciating the one-stop-shop for both TGAC certification and TVC classification. Since the inception of the services, 101 classifications have been completed, and feedback from both the clients themselves and the TV networks has been excellent.

For more information please visit [adcheck.com.au](http://adcheck.com.au)

 **200+** companies using AdCheck



pieces of advertising reviewed since launch, including TV, radio, in-store, online, print



Ran multiple training workshops to build industry expertise on the TGAC (Therapeutic Goods Advertising Code)

**Digital & Social Media Guidelines**



CHP Australia provides detailed guidelines to assist advertisers



### Highlights of the AdCheck Service Include:

**Experience** – At CHP Australia we have over 25 years of experience performing detailed advertising compliance checks and are well known as the benchmark regulatory experts in Australia for therapeutic goods. Our AdCheck team has in-depth expertise on the intricacies of the Therapeutic Goods Act, Regulations and Advertising Code, which is arguably the most detailed, complex legislation for consumer goods. We stay up to date on any changes and as the industry body representing therapeutic goods we have strong relationships with the TGA and the Department of Health and Aged Care.

**Coaching and compliance training** – Our aim is to assist you to reach compliance on any given ad. We provide coaching and advice on how to reach compliance for an ad; we don't just provide an 'it needs fixing' response.

**Unique AdCheck verification number** – CHP Australia is well known and respected throughout industry for its expertise in compliance for therapeutic goods; a CHP Australia AdCheck number assigned to compliant ads represents quality and assurance and can be verified upon request.

**Support managing complaints** – As a client of CHP Australia, if a complaint arises, we will professionally assist you as indicated in our Terms. Our expertise includes many years of dealing with complaints (CRP and CHP Australia complaints processes).

More information can be found on our website: [adcheck.com.au](http://adcheck.com.au)



# Setting the industry agenda

## SELF-CARE FOR A SUSTAINABLE AUSTRALIAN HEALTHCARE SYSTEM

Self-care is the practice of individuals managing their health using the knowledge and information available to them.

Self-care interventions are evidence-based tools supporting self-care, accessible fully or partially outside formal health services (e.g. medicines, counselling, diagnostics, digital technologies). With almost half of the world's population lacking access to essential health services, the WHO recommends self-care interventions for every country, as a critical path to reach universal health coverage, promote health and serve the vulnerable.

### The Role of Self-Care in modernising Australia's Healthcare System

Effective self-care involves collaboration between individuals and healthcare systems and services.

Growing populations demographic shifts, chronic condition management, climate change and rising infectious disease risks have increased Australia's need for healthcare access.

Australians require preventive care options and health literacy to expedite recovery when medical issues arise.

Rising chronic disease burdens and healthcare costs, along with value-based payments and innovative care models, are shifting focus from expensive specialised care to high-value self-care, supported by evidence, clinical expertise, social support and information technology.

### Responsible Use of Medicines

Globally, self-responsible use of non-prescription medicines and therapeutic goods is a crucial self-care intervention, allowing individuals to manage treatable conditions without visiting an HCP or emergency department.

In low- and middle-income countries (LMICs), access to nonprescription medicines and therapeutic goods may contribute to a reduction in healthcare disparities by offering low-threshold access to healthcare - without major disruptions to daily routines. Globally, access to these products is a crucial self-care intervention.


### Economic Benefits of Self-Care

Although Australia boasts a commendable healthcare system, there is still scope for enhancement.

Healthcare costs have risen fourfold over the last 25 years, while limited resources constrain the system. Short-term investments in self-care yield long-term savings for governments and healthcare industries, while improving health outcomes.

In Australia, maximising self-care could potentially save \$1300-\$7515 per hospital patient each year as well as lower readmission rates.

2.9-11.5% of ED services and 7-21.2% of GP services can be safely transferred to pharmacy in Australia, offering a saving of \$511M-\$1.67B each year.



## ADVOCATING FOR INCREASED CONSUMER ACCESS AND BALANCED REGULATION

CHP Australia continued its advocacy in 2023/2024 for greater consumer access to nonprescription medicines and consumer-facing medical devices as well as for proportionate, risk-based, evidence-based regulation.

### We achieved our outcomes by working collaboratively with:



PEAK HEALTHCARE PROFESSIONAL BODIES



OTHER INDUSTRY BODIES (AUSTRALIAN AND INTERNATIONAL)



MEMBERS



THE TGA



OTHER COMMONWEALTH AND STATE GOVERNMENT AGENCIES



ADVERTISERS, BROADCASTERS AND PUBLISHERS



PEAK CONSUMER BODIES



RESEARCH ORGANISATIONS

We have key contacts in over 70 organisations in addition to the Department of Health and Aged Care and the TGA.

In addition to our work with the TGA on regulatory reforms, we also continued our advocacy in relation to Sustainability, Manufacturing, Supply Chain and Exports by engaging with stakeholders, monitoring the environment, contributing to reforms and keeping members up-to-date on a wide range of issues.

#### In relation to Sustainability, these included:

- Regular meetings of the CHP Australia Sustainability Subcommittee
- Product Stewardship initiatives and exemplars
- APCO reforms and the future of the National Packaging Covenant
- DCCEEW reforms (e.g. packaging regulation and mandatory design standards, Environment Protection and Biodiversity Conservation Act)
- Global Plastics Treaty
- Microplastics
- Qenos Polyethylene plant closure impact on Australian manufacturers/sponsors
- Sustainability initiatives and reforms
- War on Waste – blister pack recycling media management
- The Therapeutic Goods Environmental Alliance (TGEA) has emerged from the Blister Pack Industry WG and will assume an oversight role (being comprised of secretariat representatives from CHP Australia, CMA, GBMA and MA)
- Ongoing, regular, contact with Australian recyclers
- Ongoing advocacy in relation to the three action areas identified by the Global Self Care Federation with input from the Sustainability Subcommittee: Plastics and packaging, Pharmaceuticals in the Environment, CO2 Footprint
- Membership and feedback into GSCF Environmental Sustainability WG and Blister Pack Taskforce

#### In relation to Manufacturing, Supply Chain and Exports these included:

- Ongoing membership and participation on DISR's Supply Chain Roundtable (SCRT)
- IPEF (Indo-Pacific Economic Forum) briefings for industry
- PIC/S updates and adoptions
- Supply Chain Resilience Initiatives – ongoing monitoring
- TGA's Medicine Shortages Working Party (MSWP) and Medicines Shortages Section
- Adoption of Annex 16 to the PIC/S and impact on Release for Supply
- Development of revised Technical Guidance for RFS
- CM TWG (API premixes)
- Allergens, cleaning validation and labelling (GMP and labelling impacts)
- APIs approved for use in both Listed and Register medicines – same ingredient/same source/same Route of Administration - differing GMP requirements
- Probiotics guidance and practicalities for testing requirements as part of manufacture and stability testing.
- GMP/Technical Agreement Template project
- Vendor Qualification Questionnaire update project
- Membership of the TGA's ComTech Forum and TIWGG (CM TWG and RFS TWG)

## Leading on Issues Management

CHP Australia is the voice of the consumer healthcare products industry with external stakeholders and in the media. CHP Australia advocates for issues important to the industry, promotes the economic and social value of the industry, protects the sector's reputation, and supports consumer education about the responsible use of nonprescription medicines, consumer-facing medical devices and self-care.

CHP Australia continues to build on our advocacy efforts - accommodating shifting policy priorities and adjusting to changes in the political landscape – to ensure members' concerns and issues are being heard in all appropriate forums.

We have seen **meaningful** outcomes that are important to members, most notably:

In our efforts to meet the challenges and navigate the limitations of the pandemic environment.

By working collaboratively with stakeholders and advocacy partners, and closely monitoring the political environment, CHP Australia has been able to deliver results for members in a crowded advocacy and communications environment. Most notably:

- The promotion of a National Health Literacy Strategy, and National Consumer Engagement Strategy for Health and Wellbeing being prioritised within the Department of Health and Aged Care.

- Strong advocacy to elevate the role of self-care in the final National Preventive Health Strategy.

- Won significant elevation of self-care principles in the Strengthening Medicare Taskforce Report.

- Engaged with TGA and Minister for Industry on potential IP protections for Switch (down scheduling of S4 products to S3).

- Engaged with Minister for Health and Aged Care and Minister for Foreign Affairs on WHO's resolution on Self-Care.

- Led efforts with government and industry stakeholders to address NRT importation regulation barriers.

- Contributed non-regulatory insights and feedback to five different Government Departments, Committees and advisory bodies via 14 submissions.

- Sponsored the development and roll out of the Life Education's Anti-Vaping Module. The module began running in schools in January 2024, and 20,000 are expected to complete the module this school year. CHP Australia has been recognised as sponsors of the program in all advertising material and media.

- Our Stakeholder Breakfast in Australian Parliament House saw significant increase in political engagement including attendance by Assistant Minister for Health and Aged Care, Emma McBride MP, 2 Senior Ministerial Advisors (Office of the Minister for Health and Aged Care, and Office of the Prime Minister), 4 MPs, and 5 non-government stakeholders. The event also resulted in 16 profile-building engagements from MPs who could not attend our event.

- We continued to contribute to and promote insightful global and local research, including research that demonstrates the economic, social and health benefits of consumer empowerment in health and the opportunities available through greater self-care.



# Driving Regulatory Reform

CHP Australia continued to influence outcomes at a time of unprecedented regulatory reform. Our work with members, the TGA and other stakeholders drives outcomes that are practical, proportionate, effective and implemented within realistic timeframes.

In the 12 months since July 2023, we had over 200 meetings with external stakeholders (including over 50 meetings with the TGA). In the same period, we considered 61 regulatory consultations and made submissions in relation to 39. Through our Teams, Working Groups and Subcommittees we discussed reforms and issues with members and agreed on industry positions. Through hundreds of interactions with individual members we explored regulatory complexities and provided support and advice to members.

This close collaboration between the Secretariat, the Members and other stakeholders is what drives our advocacy.



## Advertising

Therapeutic Goods advertising continues to be a major concern for members. Throughout the year, our advocacy has involved participation in the TGA consultations (public and targeted), advice to members, member workshops, meetings with the TGA and meetings with other stakeholders. In particular, our membership of the Therapeutic Goods Advertising Consultative Committee (TGACC) has allowed us to influence discussions and to obtain valuable insights for our members. Key activities included:

- Close liaison with the TGA to project our views
- Close liaison with members to identify issues, to provide solutions and to assist navigating the TGAC and associated guidelines (especially in relation to scientific or clinical representations, sampling, testimonials and endorsements)
- Liaison with other stakeholders to socialise the CHP Australia positions
- Detailed responses to public and targeted consultations
- Assisting members with the TGA's complaints processes and sanctions regime
- Ongoing monitoring of emerging advertising issues (e.g. greenwashing)



## TGA's Digital Transformation Program

Through collaboration, feedback and participation, we are working to ensure that the consumer healthcare perspective is being properly incorporated into the TGA's Digital Transformation Project. Key activities included:

- CHP Australia is now a member of the TGA's Digital Transformation IWG
- Advancing members' interests
- Receiving regular updates from the TGA and providing to members
- Inclusion as a standing agenda item at Liaison meetings
- Collecting issues to be addressed
- Secretariat and Member feedback to

## TGA

- Secretariat and member participation on TGA pilots, working groups and webinars
- Feedback on various manufacturing, registration/listing and scheduling reforms related to this project



## Medical Device Reforms

Building on previous years, we have continued to explore opportunities to grow and develop our expertise in relation to Medical Devices and to influence outcomes. Our membership of the TGA's RegTech Forum has allowed us to influence discussions and to obtain valuable insights for our members. Key activities included:

- Membership of, and active participation at, the TGA's RegTech Forum
- Regular meetings of the CHP Australia Devices Working Group
- Attendance at relevant workshops, webinars and seminars
- Participation in public and targeted consultations
- Submissions were made in relation to:
  - Proposed application audit framework
  - Conformity Assessment Process Change Workshop



- Proposal for UDI requirements for retail only supply
- Evaluation processes and timeframes for TGA Conformity Assessment certificates
- Proposal for regulation of exempt medical devices and exempt other therapeutic goods
- Availability of Instructions for Use in more flexible formats
- Medicine / medical device boundary and combination products
- Medical devices containing substances or materials of animal, microbial or recombinant origin
- Based on our feedback, ARCS is now offering training courses on medical device regulation
- Ongoing advocacy re UDI for retail devices
- Ongoing advocacy re medicine / medical device boundary products



### Scheduling and Scheduling Environment

Throughout the year we continued to assist members and collaborate with stakeholders to facilitate successful switch applications. We also worked with stakeholders to address obstacles to Appendix M implementation and scheduling issues as they arose. Key activities included:

- NSW Poisons Advisory Committee membership
- Liaison with TGA and pharmacist organisations on App M
- Submissions to ACMS/ACCS in support of members and down-scheduling generally
- Submissions to ACMS/ACCS identifying unintended consequences of proposals (e.g. from the TGA's "de-duplication" project)
- Submissions to ACMS/ACCS were made in relation to:
  - Amygdalin and Hydrocyanic Acid
  - Dextromethorphan

- Dihydrocodeine
- Ethyl Lactyl Retinoate
- Glycopyrronium
- Methenamine
- Nicotine
- Palmitoylethanolamide (PEA)
- Paracetamol
- Tranexamic Acid
- Submissions to the TGA were made in relation to:
  - Guidance on scheduling processes
  - Inclusion of CAS numbers in the Poisons Standard
  - Guidance on derivatives
  - Alignment and streamlining of the TGA's down-scheduling and product application processes
- Active role in the paracetamol re-scheduling transition to ensure a pragmatic, nationally consistent approach to label exemptions with the TGA and the States and Territories
- A CHP Australia paper examining incentives for switch was developed and endorsed by the membership. Feedback on the paper was sought from the TGA. Based on this feedback, work is being re-focussed on other ways to assist scheduling applicants (e.g. Application consortia, Increased use of Appendix M and Better alignment of TGA processes, etc)
- Assisted members after scheduling decisions, for example with effective dates, State and Territory labelling exemptions, product applications, etc
- Monitoring of the NZ classification environment with submissions made in relation to:
  - Benzydamine
  - Flurbiprofen
  - Ibuprofen
  - Low Dose Cannabidiol
  - Naproxen
  - Lidocaine Teething Gels
  - Paracetamol
  - Zinc Oxide



### Others

We also provided advocacy and member assistance to drive meaningful change across a wide range of other regulatory areas and issues, some of which included:

- Aspartame safety
- Cannabis and CBD reforms
- Child-resistant packaging standards
- Compounding pharmacies (e.g. OTC replicas and "bulk" compounding)
- De-duplication project for 26BB/Poisons Standard
- Dextromethorphan (safety, efficacy, international developments)
- E-Cigarettes (vaping reforms, NRT capture, NRT indications)
- Consumer Medicine Information (Electronic Distribution Working Group)
- Evidence guidelines (for Assessed Listed medicines)
- Fish oil (consideration of CV risks)
- GMP (Timeframes for Clearance and Extension applications)
- Greenwashing
- Herbal ingredient application requirements and characterisation
- Herbal ingredient safety
- Labelling – priorities for future updates to TGO 92 (e.g. Large oral dosage forms size restrictions)
- Listed ingredients approvals - TGA imposing a duration of use, or other restrictions, in 26BB for new substances
- Overuse of multiple micronutrients in pregnancy
- Paracetamol (labelling, adverse events, behavioural effects, purported lack of efficacy, patterns of overdose, NZ classification)
- Pharmacovigilance – updated reporting requirements on serious safety issues (SSI)
- Pharmacovigilance – updates to guidance
- Phenylephrine (US developments)
- PI flavours and fragrances application

requirements

- Probiotics (quality, naming, strain ID, labelling, etc)
- Proposed changes to permissible indications determination (annual update)
- Pseudoephedrine (NZ changes, EU safety, EU scheduling)
- New Zealand legislative reforms – Therapeutic Products Bill including Natural Health Products
- Nitrosamines
- OTC Medicines applications (transparency and timeframes)
- OTC Changes project
- Permissible Ingredients Determination (processes for addition of ingredients or ingredient changes)
- Real World Data and Real World Evidence
- SHPA publication re analgesics on retail display



### Emerging issues

- CHP Australia's secretariat are able to keep members up-to-date through our:
- Membership of GSCF Working Groups and Subcommittees
- Close collaboration with sister organisations such as AESGP, CHPA, CHPNZ, FHCP and PAGB
- Regular contact and liaison with more than 70 Australian organisations and government depts
- Environmental monitoring
- Issuing ALERTs and FYIs to the members
- Liaising with members individually and collectively



# Sustainability at CHP Australia

During the 2023-24 year, CHP Australia continued to build on our commitment and support for members' sustainability objectives, introducing a dedicated sustainability pillar into the CHP Australia 2024-2026 strategic plan to reflect that this is a high priority area for action and member support.

Plastics and packaging have remained a key focus area in response to policy calls emerging from the State and Territory Environment Ministers regarding greater circularity in the management of products and packaging in Australia. We have continued our advocacy regarding the opportunities and challenges for the consumer healthcare products industry regarding packaging regulation in both targeted consultation and the public consultation. The Packaging Regulation Reforms from the Department of Climate Change, Energy, the Environment, and Water (DCCEEW) have been a high focus and priority for members.

Key areas of focus for members for sustainability include:

Plastics and Packaging:

- UN Global Plastics Treaty
- DCCEEW packaging regulation reforms and mandatory design standards
- APCO 2030 strategic plan for circular economy and implementation of eco-modulated fees
- Advocating for resourcing of advanced recycling infrastructure to DISR/DCCEEW
- Continuing work on the Blister Pack recycling project
- Members working on supply chains and exploring more recyclable packaging formats
- Education and information sharing on RecyClass framework
- Changes to NZ kerbside recycling regulations and exploring pathways for advocating for harmonisation

Pharmaceuticals in the Environment:

- IChEMS framework and ongoing concerns about where medicines regulation could intersect with Industrial Chemicals regulation
- Maintaining a watch on global developments, including the EU's revised Urban Wastewater Treatment Directive allocating substantial costs to medicines and cosmetics industries based on a "polluter pays" principle.

CO2 footprint:

- Emissions reporting obligations – mandatory for certain businesses under the Climate Related Financial Disclosures requirements that commenced in 2024



CHP Australia's partnership with Life Education has continued to grow, with our vaping module for year 5 and 6 students being rolled out in classrooms in the 2024 school year.

Using the most innovative pedagogical practices, and newest technologies, the module aims to engage over 20,000 students by the end of 2024, as well as providing support for both teachers and guardians.

The new technologies used in this module bring numerous opportunities to build on their initial delivery, and we look forward to supporting Life Education in their next steps.



In addition to contributing to various consultations and meetings, CHP Australia has proudly endorsed the Australian Self-Care Alliance's Self-Care Charter, which promotes self-care to policy-makers, healthcare professionals and consumers. The Self-Care Charter identifies that in order to practice good self-care, consumers need:

- Knowledge,
- Access,
- Choices,
- Opportunity,
- A National Self-Care Strategy,
- E-Health technologies,
- Low-Cost care,
- Healthcare workers,
- Services working together, and
- Research



CHP Australia's sponsorship of Sydney North Primary Health Network's GPs in Schools program has continued for a fourth year.

Through our partnership, the GPs in Schools program has reached 4000-5000 students at approximately 30 schools, with over 80 GPs and nurses delivering contextually relevant health literacy education to year 11 students across the Primary network.

GPs in Schools is a one of a kind program, that we are supporting to advocate for broader government support, so that the invaluable program can be delivered to year 11 students across a wider setting.



CHP Australia has been actively engaging with GSCF on various working groups including the GSCF Board, Environmental Sustainability Working Group, Regulatory Affairs Committee, Communications and Public Affairs Committee, Policy Committee, and other ingredient-specific issues and campaigns.

Notable actions from GSCF include:

- International Self-Care Day 2024 campaign "Self-Care is Healthcare"
- Establishing an Anti-Microbial Resistance (AMR) Task Force to defend OTC products from being inadvertently caught up at the 79th United Nations General Assembly
- Delivering a session on Self-Care Literacy for All at the Global Health Literacy Summit in Rotterdam
- Spearheading the development of guidelines on stability, the revision of M4Q(R1) CTD on Quality guidance, and Bioequivalence for Immediate-Release Solid Oral Dosage Forms and Quality Risk Management at the International Council for Harmonization Assembly.
- The launch of a Real World Evidence & Data playbook

# CHP Australia Board



**Dr. Aniss Chami**  
Vitex Pharmaceuticals



**Alison Holland**  
Aspen Pharmacare



**Andrew Jenkin**  
iNova Pharmaceuticals  
(Vice-Chair)



**Phil Lynch**  
Chair



**Alan Oppenheim**  
Ego Pharmaceuticals



**Nadia Stone**  
Kenvue



**Sylvain Vigneault**  
Viatris



**Anish Patel**  
Haleon



**Ayumi Uyeda**  
Bayer

## CHP Australia Board Composition

The CHP Australia Board composition, nomination, elections and executive roles are all governed by the CHP Australia Constitution.

The CHP Australia Board consists of up to ten Directors as follows:

- Up to six Directors elected from the Official Delegates of the CHP Australia Ordinary Members (Elected Directors)
- Up to four Directors appointed by the Board (Skills-based Directors)

The Elected Directors each hold office for two years and every year three of the Elected Directors retire from the Board. In advance of each annual retirement, CHP Australia calls for expressions

of interest and holds elections for the three Director positions to be vacated. This ensures that there are opportunities for new Directors while maintaining continuity of expertise.

While each Elected Director must be the Official Delegate of an Ordinary Member, the Skills-based Directors can be drawn from a much wider set of candidates (including, for example, Honorary Life Members, Associate Members and non-members).

The CHP Australia Elected Directors as at 30 June 2024:

- Aniss Chami**, Vitex Pharmaceuticals
- Alison Holland**, Aspen Pharmacare

• **Andrew Jenkin**, iNova Pharmaceuticals (Vice Chair)

• **Alan Oppenheim**, Ego Pharmaceuticals

• **Anish Patel**, Haleon

• **Nadia Stone**, Kenvue

The CHP Australia Skills-based Directors as at 30 June 2024:

• **Phil Lynch** (Chair)

• **Sylvain Vigneault**, Viatris

There is currently one vacancy on the Board for a Skills-based Director

## CHP Australia Members

### Ordinary Members (at time of printing)

abbvie

arretex

aspen  
AUSTRALIA

BAXTER  
LABORATORIES



CHURCH & DWIGHT  
AUSTRALIA

COMBE

ego  
the science  
of healthy skin

ENSIGN  
LABORATORIES

FirebrickPharma

H.W Woods Pty Ltd

HALEON

inova  
pharmaceuticals

kenvue

Nestle

ORGANON

symbion

Tismor  
HEALTH & WELLNESS

VIATRIS

vitex  
pharmaceuticals

### Associate Members (at time of printing)

THE 6<sup>A</sup> AGENCY

Archer Emery & Associates

AVICENNA  
CONSULTING

bread

Circana

CUBE<sup>+</sup>

Engel, Hellyer &  
Partners Pty Ltd

eurofins

| Dermatest

gadens

iLG  
Learning Group

IQVIA

NEXUS  
PUBLIC AFFAIRS

PATHWAY  
INTERNATIONAL PTY LIMITED

pharma  
to market

Precision  
Public Affairs

Purvis  
Regulatory Consulting

Scientific & Regulatory Solutions  
Food, Beverage & Pharmaceutical Consultants

semcom

stratosphere

SA

tvsn

DIGITAL  
vine

ward 6

ENA  
TECHNOLOGIES  
Your Partner in Innovative Services

brand medicine  
international  
compound your potency

HEALTH  
INGREDIENTS  
CO.

► PHARMALEX

## Subcommittees


# Subcommittees and Working Groups

CHP Australia subcommittees and working groups provide you with the opportunity to be directly involved with CHP Australia's work programme and help deliver our strategic plan. Members of these groups meet regularly to plan activities and guide how we shape the regulatory environment, advocate on key issues and provide member services and engagement.

- Contribute to the CHP Australia position on key issues
- Shape industry work
- Keep up to date with current issues
- Meet with the TGA


We greatly value the involvement of our subcommittee and working group members and would like to thank all members who give their time to achieve our shared goals.

**For more information on how to  
get involved email us at  
[info@chpaustralia.com.au](mailto:info@chpaustralia.com.au)**



# CHP Australia – Your Support Team

CHP AUSTRALIA SECRETARIAT



## ADCHECK SERVICE



WE'RE HERE TO HELP

## General Enquiries:

Suite 1, Level 2  
35 Chandos St  
St Leonards NSW 2065

Ph: +61 2 9922 5111  
[info@cbpaustralia.com.au](mailto:info@cbpaustralia.com.au)

#### **AdCheck Enquiries**

Ph: +61 2 9922 5111  
adcheck@chpaustralia.com.au

# CHP Australia Events

## Webinars

**21 June 2023** Chat GPT: Friend or Foe with Vine Digital

**6 July 2023** Award Entry Guidance & Critical Tools in a Marketing Plan with Xpotential

**16 August 2023** Exports in a post-covid world with Peter Osborne, 6AM Agency

**5 October 2023** The Secret to Creating Social Media Videos that Captivate and Convert with Bread Agency

**26 March 2024** Consumer Health Industry Update Webinar with IQVIA

**27 June 2024** Expanding business overseas - lessons from the frontline with Peter Osborne

## TGAC Workshop

**14, 21 & 28 June 2023** Therapeutic Goods Advertising Code (TGAC) – Workshop (Virtual)

**16, 23 & 30 August 2023** Therapeutic Goods Advertising Code (TGAC) – Workshop (Virtual)

**11, 18 & 25 October 2023** Therapeutic Goods Advertising Code (TGAC) – Workshop (Virtual)

**14, 21 & 28 February 2024** Therapeutic Goods Advertising Code (TGAC) – Workshop (Virtual)

**14 March 2024** Sydney Therapeutic Goods Advertising Code (TGAC) - Workshop

**4, 11 & 18 April 2024** Therapeutic Goods Advertising Code (TGAC) – Workshop (Virtual)

**12, 19 & 26 June 2024** Therapeutic Goods Advertising Code (TGAC) – Workshop (Virtual)

## AGM

**16 November 2023**

## CHP Australia Conference and Self-Care Excellence Awards

**2 November 2023**

## Other Events

**7 & 8 May 2024** Driving Consumer Healthcare Success in Pharmacy Workshop

**8 May 2024** Executive Roundtable Lunch with Tony Lawle

**24 June 2024** CHP Australia's 50th Anniversary Self-Care Networking Breakfast

# CHP Australia Member Services

## Advice and Support

- Pool of expertise to utilise
- Confidential advice on regulatory, technical, marketing and media management issues
- Member workshops to navigate current/pending regulatory reforms

## Advocacy and Representation

- "Voice of industry" on issues impacting industry, segments, ingredients
- Member conduit to media, stakeholders, government, TGA
- Parliamentary Events
- Strength in numbers

## Shaping Industry Initiatives

- Committee, working group involvement
- Share experiences with other members
- Contribute to the CHP Australia position/shape industry work

## Staying informed

- Keep up to date on issues
- Local and international monitoring of issues with briefs and alerts to members
- E-newsletters, alerts, events, seminars, workshops, web portal

## Self Regulation

- CHP Australia Code
- CHP Australia Complaints Panel

## Member Events

- World Class Industry Events
- Education Seminars
- Member Forums
- CHP Australia's Conference and Self-Care Excellence Awards

## Member Training

- In house training and inductions
- Therapeutic Goods Advertising Training
- Member workshops

**GENERAL ENQUIRIES**

Suite 1, Level 2  
35 Chandos St,  
St Leonards NSW 2065

**Ph: +61 2 9922 5111**

Fax: +61 2 9959 3693

info@chpaustralia.com.au  
www.chpaustralia.com.au  
ABN 55 082 798 952

---

**MEMBERSHIP ENQUIRIES**

**Ph: +61 2 9059 2439**

info@chpaustralia.com.au

---

**ADCHECK ENQUIRIES**

**Ph: +61 2 9955 7205**

adcheck@chpaustralia.com.au

---

**MEDIA ENQUIRIES**

**Ph: +61 2 9059 2442**

media@chpaustralia.com.au

[chpaustralia.com.au](http://chpaustralia.com.au)



**Consumer Healthcare  
Products Australia**